Jafar Koupaie, MD
Procedural Dermatology · Riverside, CANPI 1508940644
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 150 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 32.1% of the total.
Across 150 payments — averaging $25.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$413
- Regeneron Healthcare Solutions, Inc.$390
- Janssen Scientific Affairs, LLC$302
- LEO Pharma Inc.$286
- Novartis$226
- plus $955 from 16 others
What the payments were for
- Food & beverage$3,788100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $1,217 |
| Amgen | 30 | $413 |
| Regeneron Healthcare Solutions, Inc. | 14 | $390 |
| Janssen Scientific Affairs, LLC | 3 | $302 |
| LEO Pharma Inc. | 19 | $286 |
| Novartis | 9 | $226 |
| Sanofi | 10 | $226 |
| Bristol Myers Squibb | 2 | $150 |
| Organon | 1 | $91 |
| Johnson & Johnson | 4 | $80 |
| Pfizer | 3 | $67 |
| Lilly USA, LLC | 3 | $67 |
| Verrica Pharmaceuticals Inc. | 2 | $49 |
| Genentech USA, Inc. | 2 | $46 |
| Arcutis Biotherapeutics, Inc. | 2 | $30 |
| Incyte Corporation | 1 | $28 |
| Krystal Biotech Inc | 1 | $26 |
| UCB, Inc. | 1 | $25 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| Galderma Laboratories, L.p. | 1 | $17 |
| Sun Pharmaceutical Industries Inc. | 1 | $16 |
| Biofrontera Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,788 in reported general payments places this provider in the 60th percentile of 108 procedural dermatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 59 | $232,457 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 17 | $127,224 |
| OtezlaApremilast | 21 | $101,605 |
| Dupixent SyringeDupilumab | 13 | $46,031 |
| OpzeluraRuxolitinib Phosphate | 11 | $28,007 |
| Calcipotriene | 29 | $5,740 |
| Clobetasol Propionate | 116 | $3,899 |
| Triamcinolone Acetonide | 125 | $2,243 |
| Ketoconazole | 95 | $1,573 |
| Hydrocortisone | 91 | $1,286 |
| Doxycycline Hyclate | 46 | $1,203 |
| Cephalexin | 32 | $1,191 |
| Fluorouracil | 20 | $1,129 |
| Metronidazole | 22 | $984 |
| Hydroxyzine Hcl | 123 | $913 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $413 | $101,60521 claims |
| Incyte CorporationOpzelura | $28 | $28,00711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 108 procedural dermatology providers in California.
Other procedural dermatology in Riverside
- Ethan-Quan NguyenRiverside$15K
- Sam Khalifianla Mesa$3.5M
- Sabrina FabiSan Diego$3.1M
- Natasha MesinkovskaMission Viejo$499K
- Jeanette BlackLos Angeles$492K
- Mitchel GoldmanSan Diego$425K
- Rebecca FitzgeraldLos Angeles$230K
- Suzanne KilmerSacramento$220K
- Zakia RahmanStanford$181K
- Hrak JalianSanta Monica$160K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.